Product logins

Find logins to all Clarivate products below.


Binge Eating Disorder – Epidemiology – Binge Eating Disorder

Clarivate Epidemiology’s coverage of binge eating disorder (BED) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of BED for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.

Clarivate Epidemiology’s BED forecast will answer the following question:

  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of BED over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 10 BED patient populations, as follows:

  • Total lifetime prevalent cases of BED.
  • Total 12-month prevalent cases of BED.
  • Total lifetime prevalent cases of mild BED.
  • Total lifetime prevalent cases of moderate BED.
  • Total lifetime prevalent cases of severe BED.
  • Total lifetime prevalent cases of extreme BED.
  • Total lifetime prevalent cases of BED with depression.
  • Total lifetime prevalent cases of BED with anxiety disorder.
  • Total lifetime prevalent cases of BED with bipolar disorder.
  • Total lifetime prevalent cases of BED with attention-deficit/hyperactivity disorder.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
Report
Multiple Myeloma – Geographic Focus: China – Multiple Myeloma – China In-Depth (China)
China’s multiple myeloma therapy market is evolving rapidly, driven by an increasing disease burden and advances in treatment options. Current therapies in China largely mirror global standards;…
Report
Type 2 Diabetes – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Metformin remains the most heavily prescribed type 2 diabetes (T2D) drug and dominates the early lines of therapy before disease progression requires insulin replacement. More effective, safer, and…
Report
Malignant Melanoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…